Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions
Advertisement

Related Content

Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
PPIs For Infants: FDA Summons Advisory Panel, But Industry Unenthusiastic
Takeda Buys Out Chinese Venture, Gains Flexibility In Decision-making For Commercial Expansion
Takeda Takes Global Expansion Next Door To South Korea
Takeda Cuts Jobs And Pushes Oncology After Patent Losses Nudge 2009 Sales Down 4.7%
Takeda Cuts Jobs And Pushes Oncology After Patent Losses Nudge 2009 Sales Down 4.7%
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Advertisement
UsernamePublicRestriction

Register

SC075701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel